MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 561618 | Name: Droxicam
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Droxicam is a nonsteroidal anti-inflammatory drug (NSAID) and a prodrug of piroxicam, belonging to the oxicam class. It exerts its effects by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis involved in pain and inflammation. After oral administration, it is metabolized into piroxicam, which provides its anti-inflammatory, analgesic, and antipyretic effects.

Chemical Structure

Droxicam
Droxicam
CAS#90101-16-9

Theoretical Analysis

MedKoo Cat#: 561618

Name: Droxicam

CAS#: 90101-16-9

Chemical Formula: C16H11N3O5S

Exact Mass: 357.0419

Molecular Weight: 357.34

Elemental Analysis: C, 53.78; H, 3.10; N, 11.76; O, 22.39; S, 8.97

Price and Availability

Size Price Availability Quantity
100mg USD 350.00 2 Weeks
250mg USD 700.00 2 Weeks
500mg USD 1,150.00 2 Weeks
1g USD 1,850.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Droxicam; Droxicamum; Ombolan; Droxar; Dobenam; E 3128; E3128; E-3128; E 318; E318; E-318;
IUPAC/Chemical Name
5-Methyl-3-(pyridin-2-yl)benzo[5,6][1,2]thiazino[3,4-e][1,3]oxazine-2,4(3H,5H)-dione 6,6-dioxide
InChi Key
OEHFRZLKGRKFAS-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H11N3O5S/c1-18-13-14(10-6-2-3-7-11(10)25(18,22)23)24-16(21)19(15(13)20)12-8-4-5-9-17-12/h2-9H,1H3
SMILES Code
O=C(N1C2=NC=CC=C2)OC(C3=CC=CC=C34)=C(N(C)S4(=O)=O)C1=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Droxicam is a non-steroidal anti-inflammatory drug (NSAID) for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.
In vitro activity:
TBD
In vivo activity:
TBD

Preparing Stock Solutions

The following data is based on the product molecular weight 357.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
TBD
In vitro protocol:
TBD
In vivo protocol:
TBD
1: Esteve J, Farré AJ, Roser R. Pharmacological profile of droxicam. Gen Pharmacol. 1988;19(1):49-54. doi: 10.1016/0306-3623(88)90004-3. PMID: 3278945. 2: Martínez L, Sánchez J. Pharmacokinetic profile of droxicam. Eur J Rheumatol Inflamm. 1991;11(4):10-4. PMID: 1365484. 3: Jané F, Rodríguez de la Serna A. Droxicam: a pharmacological and clinical review of a new NSAID. Eur J Rheumatol Inflamm. 1991;11(4):3-9. PMID: 1365488. 4: García González M, Sanromán AL, Herrero C, Ledo L, Moreno A, González C, Moreira V. Hepatitis por droxicam. Descripción de tres nuevos casos y revisión de la literatura [Droxicam-induced hepatitis. Description of 3 new cases and review of the literature]. Rev Clin Esp. 1994 Mar;194(3):170-2. Spanish. PMID: 8008953. 5: Bartlett A, Costa A, Martínez L, Roser R, Sagarra R, Sánchez J. The effect of antacid and ranitidine on droxicam pharmacokinetics. J Clin Pharmacol. 1992 Dec;32(12):1115-9. PMID: 1487550. 6: Anonide A, Usiglio D, Pestarina A, Massone L. Droxicam photosensitivity with dyshidrotic hand dermatitis. Int J Dermatol. 1997 Apr;36(4):318-20. doi: 10.1111/j.1365-4362.1997.tb03059.x. PMID: 9169342. 7: Berenguer M, Pérez-Aguilar F, Gisbert C, Ferreres LA, Vera-Sempere FJ, Berenguer J. Hepatitis tóxica por Droxicam [Droxicam-induced toxic hepatitis]. Rev Esp Enferm Dig. 1996 Jan;88(1):49-52. Spanish. PMID: 8616003. 8: Sánchez J, Martínez L, García-Barbal J, Roser R, Bartlett A, Sagarra R. The influence of gastric emptying on droxicam pharmacokinetics. J Clin Pharmacol. 1989 Aug;29(8):739-45. doi: 10.1002/j.1552-4604.1989.tb03409.x. PMID: 2778095. 9: Esteve A, Martínez L, Roser R, Sagarra R. Pharmacokinetics of droxicam in rat and dog. Methods Find Exp Clin Pharmacol. 1986 Jul;8(7):423-9. PMID: 3762266. 10: Maya MT, Pais JP, Ruas Da Silva J, Morais JA. A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics. Eur J Drug Metab Pharmacokinet. 1995 Oct-Dec;20(4):275-9. doi: 10.1007/BF03190244. PMID: 8983932. 11: Farré AJ, Colombo M, Fort M, Gutiérrez B, Rodríguez L, Roser R. Pharmacological properties of droxicam, a new non-steroidal anti-inflammatory agent. Methods Find Exp Clin Pharmacol. 1986 Jul;8(7):407-22. PMID: 3489870. 12: Corts Giner JR, García Borrás JJ. Double-blind, randomized and parallel comparison between droxicam and diclofenac sodium in patients with coxarthrosis and gonarthrosis. Eur J Rheumatol Inflamm. 1991;11(4):29-34. PMID: 1365487. 13: Alvarez M, Zabaleta S, Díaz de Otazu R, Galdos J, Bengoa R, García Campos F. Droxicam y colestasis severa [Droxicam and severe cholestasis]. Rev Esp Enferm Dig. 1993 Oct;84(4):276. Spanish. PMID: 8292442. 14: García-Rodríguez LA, Cattaruzzi C, Grazia Troncon M, Agostinis L, Simon G. Acute liver injury and droxicam use in the region of Friuli-Venezia Giulia. Br J Clin Pharmacol. 1995 Jul;40(1):104-5. doi: 10.1111/j.1365-2125.1995.tb04547.x. PMID: 8527260; PMCID: PMC1365040. 15: Rodríguez-de-la-Serna A, Geli-Ferrer C, Diaz-López C, Sánchez-García J. Comparative double-blind study of droxicam (new NSAID) versus indomethacin in rheumatoid arthritis. Eur J Rheumatol Inflamm. 1991;11(4):35-44. PMID: 1365489. 16: Acuña JA, de la Fuente C, Vázquez MD, Tascón ML, Gómez MI, Mata F, Sánchez- Batanero P. Electrochemical behaviour of droxicam: kinetic study in aqueous- organic media. J Pharm Biomed Anal. 2002 Jul 20;29(4):617-24. doi: 10.1016/s0731-7085(02)00041-9. PMID: 12093490. 17: Sánchez J, Bartlett A, Costa A, Estruch J, Estiarte R, Soucheiron C. Adverse events with droxicam in the early clinical trials. Eur J Rheumatol Inflamm. 1991;11(4):50-8. PMID: 1365491. 18: Acuña JA, Vázquez MD, Tascón ML, Sánchez-Batanero P. Polarographic behaviour of Aceclofenac, Tenoxicam and Droxicam in a methanol-water mixture. J Pharm Biomed Anal. 2004 Sep 21;36(1):157-62. doi: 10.1016/j.jpba.2004.04.018. PMID: 15351060. 19: Primo J, Hinojosa J, Molés JR. Hepatitis por droxicam [Hepatitis caused by droxicam]. Rev Esp Enferm Dig. 1993 Feb;83(2):138-9. Spanish. PMID: 8471357. 20: Schüetz E, Sánchez J, García-Barbal J, Sarti JF, Reuter C, Harrison FJ. Therapeutic activity, clinical and gastric tolerance of 20mg daily dose of droxicam in comparison with piroxicam in patients with degenerative joint disease. Eur J Rheumatol Inflamm. 1991;11(4):21-8. PMID: 1365486.